Effectiveness and Safety of IV Zemplar in Patients on Hemodialysis and With Secondary Hyperparathyroidism Using iPTH/100 as Initial Dose

NCT00891813 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

100

Enrollment

INDUSTRY

Sponsor class

Conditions

Secondary Hyperparathyroidism
Renal Insufficiency, Chronic
Parathyroid Hormone
Hemodialysis
Hypercalcemia

Interventions

DRUG: Zemplar (paricalcitol)

Sponsor

Abbott